Semaglutide, a glucagon-like peptide-1 (GLP-1) analog that aids in weight loss by suppressing appetite, has recently gained approval from the United States (US) Food and Drug Administration (FDA) to treat obesity in children aged ≥12 years.1,2 The approval was based on the positive findings of a rec

A recent phase 3 clinical trial demonstrated that empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, achieved a statistically significant reduction in glycated hemoglobin (HbA1c) when compared with placebo among children aged 10-17 years with type 2 diabetes (T2D) who had previously